Medulloblastoma
108
17
30
41
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
26 trials with published results (24%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.3%
9 terminated out of 108 trials
82.0%
-4.5% vs benchmark
6%
7 trials in Phase 3/4
63%
26 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 41 completed trials
Clinical Trials (108)
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
Methionine PET/CT Studies In Patients With Cancer
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
Rare CNS Tumors Outcomes &Risk
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
Digoxin Medulloblastoma Study
An Intermediate Expanded Use Trial of DFMO